ZA201707710B - Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone - Google Patents
Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasoneInfo
- Publication number
- ZA201707710B ZA201707710B ZA2017/07710A ZA201707710A ZA201707710B ZA 201707710 B ZA201707710 B ZA 201707710B ZA 2017/07710 A ZA2017/07710 A ZA 2017/07710A ZA 201707710 A ZA201707710 A ZA 201707710A ZA 201707710 B ZA201707710 B ZA 201707710B
- Authority
- ZA
- South Africa
- Prior art keywords
- conditions
- fmd
- rapamycin
- dexamethasone
- standard
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title 1
- 229960003957 dexamethasone Drugs 0.000 title 1
- 235000021439 fasting mimicking diet Nutrition 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 229940127208 glucose-lowering drug Drugs 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- 230000001235 sensitizing effect Effects 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148451P | 2015-04-16 | 2015-04-16 | |
| PCT/US2016/028055 WO2016168802A2 (en) | 2015-04-16 | 2016-04-18 | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201707710B true ZA201707710B (en) | 2019-04-24 |
Family
ID=57126369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/07710A ZA201707710B (en) | 2015-04-16 | 2017-11-14 | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160303056A1 (enExample) |
| EP (2) | EP3283073A4 (enExample) |
| JP (2) | JP2018511625A (enExample) |
| KR (1) | KR20180002677A (enExample) |
| CN (1) | CN107613979A (enExample) |
| AU (1) | AU2016248443B2 (enExample) |
| BR (1) | BR112017022244A2 (enExample) |
| CA (2) | CA3108664A1 (enExample) |
| HK (1) | HK1249858A1 (enExample) |
| IL (1) | IL255026A0 (enExample) |
| MX (1) | MX2017013133A (enExample) |
| RU (1) | RU2734774C2 (enExample) |
| WO (1) | WO2016168802A2 (enExample) |
| ZA (1) | ZA201707710B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023748A2 (pt) | 2015-05-06 | 2018-07-31 | University Of Southern California | métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso |
| RU2018131403A (ru) | 2016-02-15 | 2020-03-17 | Юниверсити Оф Саутерн Калифорния | Комбинации лекарственных средств и способы стимуляции эмбрионоподобной регенерации для лечения сахарного диабета и других заболеваний |
| AU2017261723B2 (en) | 2016-05-11 | 2023-02-09 | University Of Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases. |
| WO2018102393A1 (en) * | 2016-11-30 | 2018-06-07 | Cure Cancer Worldwide Llc | System for chemotherapy delivery and method of the same |
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| AU2019236242A1 (en) | 2018-03-15 | 2020-10-01 | University Of Southern California | Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology |
| CN113194752A (zh) | 2018-06-01 | 2021-07-30 | 康奈尔大学 | Pi3k相关疾病或病症的组合疗法 |
| WO2020191356A1 (en) * | 2019-03-21 | 2020-09-24 | Goncalves Marcus | Anti-fructose therapy for colorectal and small intestine cancers |
| JP2022530671A (ja) | 2019-04-30 | 2022-06-30 | ユニバーシティ オブ サザン カリフォルニア | アルツハイマー病（ａｄ）の介入のための断食模倣食（ｆｍｄ） |
| IT201900009954A1 (it) * | 2019-06-24 | 2020-12-24 | Fondazione Irccs Istituto Naz Dei Tumori | Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie |
| EP4164407A4 (en) * | 2020-06-14 | 2024-08-28 | L-Nutra Inc. | BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE |
| EP4180047A4 (de) * | 2020-07-10 | 2024-03-13 | Martynova, Elena Anatol'evna | Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2779282C (en) * | 2009-10-22 | 2017-12-05 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
| CA2820384A1 (en) * | 2010-12-06 | 2012-06-14 | Cure Cancer Worldwide Corporation | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| US9237761B2 (en) * | 2013-02-12 | 2016-01-19 | University Of Southern California | Methods and diets for lowering glucose and/or IGF-1 levels |
| AU2014284399B2 (en) * | 2013-07-01 | 2017-10-26 | University Of Southern California | Fasting condition as dietary treatment of diabetes |
| WO2015134837A2 (en) * | 2014-03-06 | 2015-09-11 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
-
2016
- 2016-04-18 CA CA3108664A patent/CA3108664A1/en not_active Abandoned
- 2016-04-18 RU RU2017136423A patent/RU2734774C2/ru active
- 2016-04-18 WO PCT/US2016/028055 patent/WO2016168802A2/en not_active Ceased
- 2016-04-18 JP JP2017553410A patent/JP2018511625A/ja active Pending
- 2016-04-18 HK HK18109338.2A patent/HK1249858A1/zh unknown
- 2016-04-18 KR KR1020177032463A patent/KR20180002677A/ko not_active Ceased
- 2016-04-18 BR BR112017022244A patent/BR112017022244A2/pt not_active IP Right Cessation
- 2016-04-18 CN CN201680022154.8A patent/CN107613979A/zh active Pending
- 2016-04-18 MX MX2017013133A patent/MX2017013133A/es unknown
- 2016-04-18 EP EP16780985.4A patent/EP3283073A4/en not_active Ceased
- 2016-04-18 US US15/131,586 patent/US20160303056A1/en not_active Abandoned
- 2016-04-18 CA CA2982875A patent/CA2982875C/en active Active
- 2016-04-18 EP EP23209796.4A patent/EP4299061A3/en active Pending
- 2016-04-18 AU AU2016248443A patent/AU2016248443B2/en active Active
-
2017
- 2017-10-15 IL IL255026A patent/IL255026A0/en unknown
- 2017-11-14 ZA ZA2017/07710A patent/ZA201707710B/en unknown
-
2020
- 2020-10-02 JP JP2020168000A patent/JP2021008491A/ja active Pending
-
2021
- 2021-01-12 US US17/147,280 patent/US20210137856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3283073A2 (en) | 2018-02-21 |
| RU2017136423A3 (enExample) | 2019-09-04 |
| CN107613979A (zh) | 2018-01-19 |
| HK1249858A1 (zh) | 2018-11-16 |
| CA3108664A1 (en) | 2016-10-20 |
| RU2017136423A (ru) | 2019-05-16 |
| EP4299061A2 (en) | 2024-01-03 |
| US20210137856A1 (en) | 2021-05-13 |
| AU2016248443A1 (en) | 2017-11-02 |
| RU2734774C2 (ru) | 2020-10-23 |
| KR20180002677A (ko) | 2018-01-08 |
| AU2016248443B2 (en) | 2021-03-18 |
| US20160303056A1 (en) | 2016-10-20 |
| CA2982875C (en) | 2021-10-19 |
| BR112017022244A2 (pt) | 2018-07-10 |
| IL255026A0 (en) | 2017-12-31 |
| EP3283073A4 (en) | 2019-02-13 |
| MX2017013133A (es) | 2018-09-07 |
| EP4299061A3 (en) | 2024-02-28 |
| WO2016168802A2 (en) | 2016-10-20 |
| JP2018511625A (ja) | 2018-04-26 |
| JP2021008491A (ja) | 2021-01-28 |
| CA2982875A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255026A0 (en) | A fasting-mimicking diet and glucose-lowering drugs that protect normal cells and produce cancer-susceptible states in response to rapamycin- and dexamethasone-induced standard and high-glucose conditions | |
| SG11201709321RA (en) | Preparation method for solar cell piece unit and solar cell module | |
| LT2968290T (lt) | Laikina normalių ląstelių apsauga chemoterapijos metu | |
| EP3238070A4 (en) | Memory protection with non-readable pages | |
| EP2923248A4 (en) | Reversible folio for tablet computer with reversible connection for keyboard and reading configuration | |
| EP3019936A4 (en) | Fast multi-touch post processing | |
| EP3084830A4 (en) | Liner for phase change memory (pcm) array and associated techniques and configurations | |
| GB2521562B (en) | Anti-tumor T cell immunity induced by high dose radiation | |
| EP3069171A4 (en) | Seismic data processing | |
| EP3259868A4 (en) | Protecting sensitive data security | |
| EP3088951A4 (en) | Array substrate, preparation method thereof, motherboard comprising array substrate and display apparatus | |
| EP3135678A4 (en) | Heterocyclic compound and organic solar cell comprising same | |
| EP3066496B8 (en) | Device and method for detecting neutrons and gamma rays | |
| EP3298918A4 (en) | Improvements to skull protection cell | |
| EP3198466A4 (en) | Multicore memory data recorder for kernel module | |
| EP2989491A4 (en) | CORE RADIATION DETECTOR CALIBRATION IN A BOREOILL | |
| EP3260456A4 (en) | Heterocyclic compound and organic solar cell comprising same | |
| EP3241116A4 (en) | Memory access protection using processor transactional memory support | |
| EP3140673A4 (en) | Gamma detector protection for downhole operations | |
| GB201802711D0 (en) | Design structure for reducing pre-charge voltage for static random-access memory arrays | |
| LT3024833T (lt) | Nauji indolizino dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos | |
| EP3287452A4 (en) | Heterocyclic compound and organic solar cell comprising same | |
| EP3031449A4 (en) | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same | |
| ZA201505391B (en) | Framed implementation for payment widgets | |
| EP3271828A4 (en) | Cache and data organization for memory protection |